Influenza and the Vocal Performer: Update on Prevention and Treatment

Michiel J. Bové, Shalini Kansal, Clark A. Rosen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Summary: Upper respiratory tract infections (URIs) are a major cause of morbidity among vocal arts professionals, both from their acute impairment of the vocal mechanism and their predisposing influence for the development of serious vocal sequelae. In this review, we present some of the salient features of currently available treatments effective against influenza, the virus family responsible for the most serious form of URI. At present, these include an inactivated vaccine and four antiviral drugs, each approved in the United States and many other countries for the prevention and treatment of influenza. A live attenuated vaccine is also available, and other vaccines and antiviral drugs are under development. This review details the current options available for treating both influenza and noninfluenza related URIs in the professional voice user.

Original languageEnglish (US)
Pages (from-to)326-332
Number of pages7
JournalJournal of Voice
Issue number3
StatePublished - May 2008


  • Amantadine
  • Influenza
  • Ion channel blockers
  • Neuramidase inhibitors
  • Oseltamivir
  • Rimantidine
  • Singer
  • Upper respiratory tract infection
  • Vocal arts performer
  • Zinamivir

ASJC Scopus subject areas

  • Speech and Hearing
  • LPN and LVN
  • Otorhinolaryngology


Dive into the research topics of 'Influenza and the Vocal Performer: Update on Prevention and Treatment'. Together they form a unique fingerprint.

Cite this